Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor

Cell Death and Disease

Volumn 3, Issue 10, 2012, Pages

  Lindqvist, L M ^a,b   Vikstrom I ^a,b   Chambers, J M ^c   McArthur, K ^a,b   Ann Anderson, M ^a,b,d   Henley, K J ^a,b   Happo, L ^a,b   Cluse, L ^e   Johnstone, R W ^b,e   Roberts, A W ^a,b,d   Kile, B T ^a,b   Croker, B A ^a,b   Burns, C J ^a,b   Rizzacasa, M A ^c   Strasser, A ^a,b   Huang, D C S ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Apoptosis; Homoharringtonine; Mcl 1; Protein synthesis; Silvestrol

Indexed keywords

ANTINEOPLASTIC AGENT; HOMOHARRINGTONINE; PROTEIN BAK; PROTEIN BAX; PROTEIN MCL 1; SILVESTROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL DEATH; CELL KILLING; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; EMBRYO; HUMAN; HUMAN CELL; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSLATION INITIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CELLS, CULTURED; HARRINGTONINES; HL-60 CELLS; HUMANS; K562 CELLS; MICE; MICE, INBRED C57BL; NEUTROPHILS; PEPTIDE CHAIN ELONGATION, TRANSLATIONAL; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRITERPENES;

EID: 84870479106     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.149     Document Type: Article

References (50)

1. Wang S, Rosenwald IB, Hutzler MJ, Pihan GA, Savas L, Chen JJ et al. Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am J Pathol 1999; 155: 247-255.
2. Lin YW, Aplan PD. Gene expression profiling of precursor T-cell lymphoblastic leukemia/lymphoma identifies oncogenic pathways that are potential therapeutic targets. Leukemia 2007; 21: 1276-1284.
3. Hilliard A, Hilliard B, Zheng SJ, Sun H, Miwa T, Song W et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol 2006; 177: 8095-8102.
4. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10: 484-486.
5. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
6. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 50 cap. Nature 1990; 345: 544-547.
7. Thornton S, Anand N, Purcell D, Lee J. Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 2003; 81: 536-548.
8. Lindqvist L, Pelletier J. Inhibitors of translation initiation as cancer therapeutics. Future Med Chem 2009; 1: 1709-1722.
9. Schneider RJ, Sonenberg N. Translational control in cancer development and progression. In: Mathews MB, Sonenberg N, Hershey JWB (eds). Translational Control in Biology and Medicine. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 2007, pp 401-431.
10. Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977; 72: 323-330.
11. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J. Altering chemosensitivity by modulating translation elongation. PLoS One 2009; 4: e5428.
12. Quintas-Cardama A, Kantarjian H, Cortes J. Homoharringtonine omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009; 115: 5382-5393.
13. Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des 2011; 17: 59-64.
14. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008; 118: 2651-2660.
15. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 2009; 4: e5223.
16. Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A et al. Dual Targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol. Clin Cancer Res 2012; 18: 4600-4611.
17. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA et al. The novel plantderived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009; 113: 4656-4666.
18. Koromilas AE, Lazaris-Karatzas A, Sonenberg N. mRNAs containing extensive secondary structure in their 50 non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J 1992; 11: 4153-4158.
19. Zimmer SG, DeBenedetti A, Graff Jr. Translational control of malignancy: the mRNA capbinding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000; 20: 1343-1351.
20. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007; 21: 3232-3237.
21. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007; 117: 2638-2648.
22. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 2011; 117: 156-164.
23. Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006; 5: 723-731.
24. Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389-1399.
25. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-730.
26. Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Kawata E, Nakagawa Y et al. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol 2008; 87: 507-515.
27. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
28. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007; 109: 248-255.
29. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
30. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
31. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305.
32. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003; 426: 671-676.
33. Dzhagalov I St, John A, He YW. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood 2007; 109: 1620-1626.
34. Mi Q, Kim S, Hwang BY, Su BN, Chai H, Arbieva ZH et al. Silvestrol regulates G2/M checkpoint genes independent of p53 activity. Anticancer Res 2006; 26: 3349-3356.
35. Baaske DM, Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother 1977; 12: 298-300.
36. Shimazu T, Degenhardt K, Nur EKA, Zhang J, Yoshida T, Zhang Y et al. NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev 2007; 21: 929-941.
37. Ke F, Voss A, Kerr JB, O'Reilly LA, Tai L, Echeverry N et al. BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice. Cell Death Differ 2012; 19: 915-925.
38. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009; 460: 1035-1039.
39. Sakamoto C, Suzuki K, Hato F, Akahori M, Hasegawa T, Hino M et al. Antiapoptotic effect of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and cyclic AMP on human neutrophils: protein synthesis-dependent and protein synthesis-independent mechanisms and the role of the Janus kinase-STAT pathway. Int J Hematol 2003; 77: 60-70.
40. Cencic R, Carrier M, Trnkus A, Porco JA Jr, Minden M, Pelletier J. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res 2010; 34: 535-541.
41. Adams TE, El Sous M, Hawkins BC, Hirner S, Holloway G, Khoo ML et al. Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the active analogue (-)-40-desmethoxyepisilvestrol. J Am Chem Soc 2009; 131: 1607-1616.
42. Carrington EM, Vikstrom IB, Light A, Sutherland RM, Londrigan SL, Mason KD et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci USA 2010; 107: 10967-10971.
43. Croker BA, Metcalf D, Robb L, Wei W, Mifsud S, DiRago L et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 2004; 20: 153-165.
44. Happo L, Cragg MS, Phipson B, Haga JM, Jansen ES, Herold MJ et al. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 2010; 116: 5256-5267.
45. Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 2008; 180: 341-355.
46. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009; 23: 2034-2041.
47. Zuber J, McJunkin K, Fellmann C, Dow LE, Taylor MJ, Hannon GJ et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol 2011; 29: 79-83.
48. Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol 2011; 7: 92-100.
49. Croker BA, O'Donnell JA, Nowell CJ, Metcalf D, Dewson G, Campbell KJ et al. Fasmediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. Proc Natl Acad Sci USA 2011; 108: 13135-13140.
50. Schoenwaelder SM, Yuan Y, Josefsson EC, White MJ, Yao Y, Mason KD et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009; 114: 663-666.